Sequential therapy for Helicobacter pylori infection with and without probiotics

Abstract

Background: Helicobacter pylori (H. pylori) infection is considered to be among the most common infections all around the world. Previous studies have shown that H. pylori is gaining resistance to several antibiotic agents. This prompted the clinicians to prescribe various combined therapies, including, probiotics to overcome the drug resistance. The aim of this study was to determine whether probiotics can increase the eradication rate of H. pylori infection. Materials and methods:This control trial was carried out on 106 H. pylori positive patients, assigned into two groups. Group A was treated with Amoxicillin, Pantoprazole, Tinidazol and Clarithromycin; group B was treated Familact capsules consisted of probiotics added to the same regimen administered to group A. At the end of treatment, urease breath test was done for the participants, and reported as positive or negative. T-test and Chi-square test were used for evaluation of the results, and P-value <0.05 was considered as significant.Results: H. pylori eradication rate in group B (88.5%) was significantly higher than group A (63.3%). Besides, the participants who received probiotics seemed to show lower side effects, including, bad taste and epigastric pain. Conclusion:The addition of probiotics to the sequential therapy could significantly increase H. pylori eradication rate.

The role of gastric microecological dysbiosis in gastric carcinogenesis

“…In a clinical trial, probiotics can be used as a probiotic supplement in combination with antibiotics and proton pump inhibitors to assist in eradicating Helicobacter pylori infection. The results show that the eradication rate of Helicobacter pylori in the combination therapy group (88.5%) is significantly higher than that in the monotherapy group (63.3%) ( Rafiei et al, 2021 ).…”